Almac has launched a new reagent offering providing homogeneous full-length histones with defined patterns of modification for researchers exploring key drug targets in the field of epigenetics.
 
The reagents will be offered through a catalogue of modified histones and additionally as a custom synthesis service to meet specific customer needs. The modified histone reagent provision expands Almac’s range of FLEXYTE FLT assays for epigenetic targets.
 
“This is a first class example of how Almac can harness its unique protein synthesis capability to provide a much needed source of tools to the epigenetic research field.  I am delighted that we are able to offer such capabilities,” said Dr. Charles Shields, vice president of Peptide and Protein Technologies at Almac.